It is found that knockdown of YHTDF1 significantly improves the anti-tumor response to anti-PD-L1 therapy (90), so targeting m6A regulatory factors may be a potential therapeutic approach to improve the immune potential therapeutic approach for checkpoint therapy. Here, CD274 is linked to neoplasm.